Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.43
(-0.08%)
AUD 12.43
(-0.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 231.92 Million AUD | 1493.66% |
| 2022 | 14.55 Million AUD | 355.21% |
| 2021 | 3.19 Million AUD | 345.89% |
| 2020 | 717 Thousand AUD | 44.85% |
| 2019 | 495 Thousand AUD | -96.46% |
| 2018 | 13.99 Million AUD | 2117.12% |
| 2017 | 631 Thousand AUD | -79.97% |
| 2016 | 3.15 Million AUD | 88.28% |
| 2015 | 1.67 Million AUD | -42.92% |
| 2014 | 2.93 Million AUD | -38.86% |
| 2013 | 4.79 Million AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 4.64 Million AUD | -7.1% |
| 2009 | 5 Million AUD | 119.98% |
| 2008 | 2.27 Million AUD | 140.89% |
| 2007 | 944.16 Thousand AUD | 445.86% |
| 2006 | 172.96 Thousand AUD | -59.74% |
| 2005 | 429.66 Thousand AUD | -69.3% |
| 2004 | 1.39 Million AUD | -50.64% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 24.32 Million AUD | 0.0% |
| 2023 Q2 | 62.92 Million AUD | 0.0% |
| 2023 FY | 231.92 Million AUD | 1493.66% |
| 2023 Q4 | 168.99 Million AUD | 0.0% |
| 2022 Q4 | 14.55 Million AUD | 0.0% |
| 2022 FY | 14.55 Million AUD | 355.21% |
| 2022 Q2 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 FY | 3.19 Million AUD | 345.89% |
| 2021 Q4 | 3.19 Million AUD | 0.0% |
| 2020 FY | 717 Thousand AUD | 44.85% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q4 | 717 Thousand AUD | 0.0% |
| 2019 FY | 495 Thousand AUD | -96.46% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q4 | 495 Thousand AUD | 0.0% |
| 2018 Q4 | 13.99 Million AUD | 0.0% |
| 2018 FY | 13.99 Million AUD | 2117.12% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q4 | 631 Thousand AUD | 0.0% |
| 2017 FY | 631 Thousand AUD | -79.97% |
| 2016 Q2 | 162 Thousand AUD | 0.0% |
| 2016 FY | 3.15 Million AUD | 88.28% |
| 2016 Q4 | 2.98 Million AUD | 0.0% |
| 2015 Q4 | 61 Thousand AUD | 0.0% |
| 2015 FY | 1.67 Million AUD | -42.92% |
| 2015 Q2 | 1.61 Million AUD | 0.0% |
| 2014 Q2 | 1.42 Million AUD | 0.0% |
| 2014 Q4 | 1.5 Million AUD | 0.0% |
| 2014 FY | 2.93 Million AUD | -38.86% |
| 2013 Q4 | 2.04 Million AUD | 0.0% |
| 2013 FY | 4.79 Million AUD | 0.0% |
| 2013 Q3 | - AUD | -100.0% |
| 2013 Q2 | 2.74 Million AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 Q1 | - AUD | 0.0% |
| 2011 Q3 | - AUD | 0.0% |
| 2011 Q1 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q3 | 1.16 Million AUD | 0.0% |
| 2010 Q1 | 1.16 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 FY | 4.64 Million AUD | -7.1% |
| 2010 Q2 | 1.16 Million AUD | 0.0% |
| 2009 Q2 | 1.25 Million AUD | 0.0% |
| 2009 Q4 | 1.16 Million AUD | -7.1% |
| 2009 Q1 | 1.25 Million AUD | 0.0% |
| 2009 Q3 | 1.25 Million AUD | 0.0% |
| 2009 FY | 5 Million AUD | 119.98% |
| 2008 Q2 | 568.59 Thousand AUD | 0.0% |
| 2008 Q3 | 568.59 Thousand AUD | 0.0% |
| 2008 Q4 | 1.25 Million AUD | 119.98% |
| 2008 FY | 2.27 Million AUD | 140.89% |
| 2008 Q1 | 568.59 Thousand AUD | 0.0% |
| 2007 Q3 | 236.04 Thousand AUD | 0.0% |
| 2007 Q1 | 236.04 Thousand AUD | 0.0% |
| 2007 FY | 944.16 Thousand AUD | 445.86% |
| 2007 Q4 | 568.59 Thousand AUD | 140.89% |
| 2007 Q2 | 236.04 Thousand AUD | 0.0% |
| 2006 Q4 | 236.04 Thousand AUD | 445.87% |
| 2006 Q3 | 43.24 Thousand AUD | 0.0% |
| 2006 FY | 172.96 Thousand AUD | -59.74% |
| 2006 Q1 | 43.24 Thousand AUD | 0.0% |
| 2006 Q2 | 43.24 Thousand AUD | 0.0% |
| 2005 Q1 | 107.41 Thousand AUD | 0.0% |
| 2005 Q2 | 107.41 Thousand AUD | 0.0% |
| 2005 Q3 | 107.41 Thousand AUD | 0.0% |
| 2005 Q4 | 43.24 Thousand AUD | -59.74% |
| 2005 FY | 429.66 Thousand AUD | -69.3% |
| 2004 Q2 | 379.13 Thousand AUD | 0.0% |
| 2004 FY | 1.39 Million AUD | -50.64% |
| 2004 Q4 | 107.41 Thousand AUD | -71.67% |
| 2004 Q1 | 379.13 Thousand AUD | 0.0% |
| 2004 Q3 | 379.13 Thousand AUD | 0.0% |
| 2003 Q1 | 708.94 Thousand AUD | 0.0% |
| 2003 Q3 | 708.94 Thousand AUD | 0.0% |
| 2003 FY | 2.83 Million AUD | 33.68% |
| 2003 Q4 | 379.13 Thousand AUD | -46.52% |
| 2003 Q2 | 708.94 Thousand AUD | 0.0% |
| 2002 FY | 2.12 Million AUD | 0.0% |
| 2002 Q1 | 530.33 Thousand AUD | 0.0% |
| 2002 Q2 | 530.33 Thousand AUD | 0.0% |
| 2002 Q3 | 530.33 Thousand AUD | 0.0% |
| 2002 Q4 | 708.94 Thousand AUD | 33.68% |
| 2001 Q4 | 530.33 Thousand AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | -13245.912% |
| Acrux Limited | 5.09 Million AUD | -4455.588% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -5108.588% |
| Biome Australia Limited | 13 Million AUD | -1682.818% |
| BTC Health Limited | 16.36 Thousand AUD | -1417534.474% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -3009.891% |
| CSL Limited | 22.41 Billion AUD | 98.965% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | -1915.571% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | -163.018% |
| Noxopharm Limited | 2.4 Million AUD | -9562.43% |
| PharmAust Limited | - AUD | -Infinity% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -25896.393% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -6147.367% |
| PYC Therapeutics Limited | 22.05 Million AUD | -951.37% |
| Race Oncology Limited | 4 Million AUD | -5693.099% |
| Starpharma Holdings Limited | 8.28 Million AUD | -2697.985% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | -249.057% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -38437.27% |
| Memphasys Limited | 60 Thousand AUD | -386441.667% |
| Nyrada Inc. | - AUD | -Infinity% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 53.303% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -1265866.157% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -244154.992% |
| Patrys Limited | 1.39 Million AUD | -16535.429% |
| Dimerix Limited | 583.47 Thousand AUD | -39648.714% |
| Orthocell Limited | 5.31 Million AUD | -4263.286% |
| Imugene Limited | - AUD | -Infinity% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -9915.577% |
| Immutep Limited | 3.5 Million AUD | -6515.613% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -1364164.706% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -5670.305% |
| Nanollose Limited | 12.5 Thousand AUD | -1855151.58% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -19031.685% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -18430.651% |
| Biotron Limited | - AUD | -Infinity% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -77407.787% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -152241.697% |
| AnteoTech Limited | 460.39 Thousand AUD | -50275.002% |
| Hexima Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -352369.605% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -48875.718% |
| Actinogen Medical Limited | 9.93 Million AUD | -2235.245% |
| Immuron Limited | 4.9 Million AUD | -4630.397% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -8827.276% |